Solutia Reports Third Quarter 20...(Ended Ended Ended ...)

Date:10/26/2009

Ended Ended Ended March 31, June 30, September 30, (in $millions, except per share data) 2009 2009 2009 ---- ---- ---- Income (Loss) from continuing operations before tax $(11) $35 $43 Net Income attributable to noncontrolling interest - 1 2 --------------------------- --- --- --- Income (Loss) from continuing operations before tax attributable to Solutia (11) 34 41 Non-GAAP Adjustments (1) (1) 10 16 ------------------------ --- --- --- Adjusted earnings from continuing operations before tax (12) 44 57 Income tax (expense) benefit on adjusted earnings 7 (12) (13) ------------------------------- --- --- --- Adjusted earnings for adjusted EPS $(5) $32 $44 --------------------- --- --- --- Diluted Shares (millions) ------------------------- Weighted average shares outstanding 93.27 95.46 118.42 Assumed conversion of Restricted Stock 0.00 0.14 0.15 -------------------------------- ---- ---- ---- Total Diluted Shares 93.27 95.60 118.57 -------------------- ----- ----- ------ Adjusted EPS (0.05) 0.33 0.37 ------------ ----- ---- ---- (1) See table of Summary of Events Affectin
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009